The MMV 2017–2021 Business Plan has been developed to support the achievement of internationally agreed targets for malaria control and elimination, as outlined in the World Health Organization (WHO) Global Technical Strategy for Malaria 2016–2030 (GTS) and the United Nations (UN) Sustainable Development Goals (SDGs). The plan also includes a longer-term perspective on the tools needed to continue the effort against malaria post-2030, in a push towards eradication as outlined in the UN Special Envoy and Bill & Melinda Gates Foundation (BMGF) call to action – From Aspiration to Action.
Achieving these global targets will require intensified investment and effort, coupled with transformative tools from MMV and other groups working on medicines, diagnostics, vector control and vaccines. MMV will focus on developing quality medicines to treat and prevent malaria in support of the global agenda:
- MMV’s strategic priorities for 2017–2021 are aligned with the unmet drug development needs at each stage of a country’s journey towards malaria elimination.
- MMV’s intent, in partnership with industry and academia, is to contribute to the discovery and early development of compounds in a flexible and pragmatic manner, and includes a post-approval commitment.
Core to MMV’s model:
- Cost- and risk-sharing
- Incentivizing drug development with partners
- Partnering with manufacturing and distribution capabilities prior to Phase III
- Contractual obligations that include making medicines available and affordable in malariaendemic countries